Irene Orlow, MS & PhD

Attending Biologist & Laboratory Member

Irene Orlow, Attending Biologist & Laboratory Member

Office Phone


Office Fax



University of Buenos Aires

Current Research Interests/Research Goals

Dr. Orlow directs the Molecular Epidemiology Laboratory. Her research interests include the study of individual (host) and tumor (somatic) genetics, phenotypic characteristics, and exposures that modulate cancer prognosis in patients with melanoma, breast, lung, and other. She is an active member of the international Genes, Environment, and Melanoma (GEM) Study group since the year 2000, as well as the international InterMEL consortium since 2017.  Studies within GEM include research on the vitamin D receptor gene variants in presence or absence of sun exposure, and chemokine/chemokine receptor variants, and their role as modifiers survival.  Dr. Orlow collaborates with members of the Dermatology Service to evaluate the effect of genetics, phenotypic characteristics, and exposures to further the knowledge of the biology and epidemiology of nevi —a known risk factor for melanoma. She is also evaluating the utility of a novel minimally-invasive technique to help diagnose early stage melanoma from other less fatal skin cancers and banal skin lesions.
Dr. Orlow collaborates with colleagues from other Departments at MSK in one other area of great interest to her, with the goal of understanding the underlying biology responsible for, and potential risk predictors for changes in cognition, and of sleep patterns, in cancer survivors.
Her lab supports additional multidisciplinary investigations, and houses biosample collections for large epidemiologic studies including, among others GEM, InterMEL, WECARE, the National Colonoscopy Study, EDGE, and CASH.



Selected peer-reviewed publications:

  1. Orlow I, Tommasi DV, Bloom B, Ostrovnaya I, Cotignola J, Mujumdar U, Busam KJ, Jungbluth AA, Scolyer RA, Thompson JF, Armstrong BK, Berwick M, Thomas NE, Begg CB. Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. J Invest Dermatol, 129(8):1972-1982, 2009. PMC2745834
  2. Cotignola J, Chou JF, Roy P, Mitra N, Busam K, Halpern AC, and Orlow I. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma. J Invest Dermatol 132:1471-1478, 2012. PMID:22336942
  3. Correa DD, Satagopan J, Baser RE, Cheung K, Richards E, Lin M, Karimi S, Lyo J, DeAngelis LM, Orlow I. Apolipoprotein E polymorphisms and cognitive functions in patients with brain tumors. Neurology 83:320-327, 2014. PMC4115606
  4. Gibbs DC, Orlow I, Bramson JI, Kanetsky PA, Luo L, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Sharma A, La Pilla E, From L, Busam KJ, Cust AE, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group. Association of Interferon Regulatory Factor-4polymorphism rs12203592 with divergent melanoma pathways. J Natl Cancer Inst.108(7) 1-9, 2016. PMC4948568
  5. Orlow I, Reiner AS, Thomas NE, Roy P, Kanetsky PA, Luo L, Paine S, Armstrong BK, Kricker A, Marrett LD, Rosso S, Zanetti R, Gruber SB, Anton-Culver H, Gallagher RP, Dwyer T, Busam K, Begg CB, Berwick M; GEM Study Group. Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: a population-based study. Carcinogenesis. 37(1):30-8, 2016. PMC4715233

View a full listing of Irene Orlow’s journal articles.